Comparative Pharmacology
Head-to-head clinical analysis: DEXONE 4 versus PREDNISONE INTENSOL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DEXONE 4 versus PREDNISONE INTENSOL.
DEXONE 4 vs PREDNISONE INTENSOL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dexamethasone is a long-acting glucocorticoid receptor agonist, binding to glucocorticoid response elements to modulate gene transcription, resulting in anti-inflammatory, immunosuppressive, anti-allergic, and anti-shock effects.
Prednisone is a prodrug that is converted to prednisolone, which binds to the glucocorticoid receptor, modulating gene expression to produce anti-inflammatory and immunosuppressive effects by inhibiting phospholipase A2, reducing prostaglandin and leukotriene synthesis, and suppressing cytokine production.
Oral: 0.75–9 mg/day divided every 6–12 hours; IV/IM: 0.5–9 mg/day divided every 6–12 hours.
5-60 mg orally once daily or divided twice daily, titrated to response.
None Documented
None Documented
Terminal elimination half-life: 2-3 hours (oral); clinical effects persist longer due to glucocorticoid receptor-mediated genomic actions
2-4 hours (terminal) for prednisone; prednisolone half-life 2-4 hours. Clinical context: shorter than anti-inflammatory effect due to delayed receptor-mediated action.
Renal excretion of metabolites (<5% unchanged drug); minor biliary/fecal elimination (<1%)
Renal: <30% unchanged; major metabolites (prednisolone, 20-dihydroprednisolone) conjugated and excreted in urine. Fecal: <10%.
Category C
Category D/X
Corticosteroid
Corticosteroid